{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:47:12Z","timestamp":1760057232721,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1 T32 HL129974-01"],"award-info":[{"award-number":["1 T32 HL129974-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA037317","R01DA048009"],"award-info":[{"award-number":["DA037317","R01DA048009"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ajem.2021.10.012","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T02:54:36Z","timestamp":1634093676000},"page":"114-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity"],"prefix":"10.1016","volume":"51","author":[{"given":"Siri","family":"Shastry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishak","family":"Nobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa R.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne D.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavey","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex F.","family":"Manini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"National Institute of Health (NIH)","key":"10.1016\/j.ajem.2021.10.012_bb0005"},{"author":"Centers for Disease Control and Prevention (CDC)","key":"10.1016\/j.ajem.2021.10.012_bb0010"},{"issue":"9","key":"10.1016\/j.ajem.2021.10.012_bb0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.15585\/mmwr.mm6709e1","article-title":"Vital signs: trends in emergency department visits for suspected opioid overdoses - United States, July 2016\u2013September 2017","volume":"67","author":"Vivolo-Kantor","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.ajem.2021.10.012_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.ajem.2021.10.012_bb0025","doi-asserted-by":"crossref","first-page":"e196373","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ajem.2021.10.012_bb0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/acem.12658","article-title":"Clinical risk factors for in-hospital adverse cardiovascular events after acute drug overdose","volume":"22","author":"Manini","year":"2015","journal-title":"Acad Emerg Med"},{"issue":"3","key":"10.1016\/j.ajem.2021.10.012_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0196-0644(96)70264-0","article-title":"Chart reviews in emergency medicine research: where are the methods?","volume":"27","author":"Gilbert","year":"1996","journal-title":"Ann Emerg Med"},{"year":"2006","series-title":"Lexicon of Alcohol and Drug Terms Published by the World Health Organization","author":"World Health Orgnization (WHO)","key":"10.1016\/j.ajem.2021.10.012_bb0040"},{"key":"10.1016\/j.ajem.2021.10.012_bb0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths \u2014 United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.ajem.2021.10.012_bb0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11606-019-05249-3","article-title":"US ED opioid-related visits increase, while use of medication for opioid use disorder undetectable, 2011-2016","volume":"35","author":"Shastry","year":"2020","journal-title":"J Gen Intern Med"},{"year":"2017","series-title":"Trends in the Use of Methadone, Buprenorphine, and Extended-release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update). The CBHSQ Report: August 22, 2017","author":"Alderks","key":"10.1016\/j.ajem.2021.10.012_bb0055"},{"issue":"1","key":"10.1016\/j.ajem.2021.10.012_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J Neurosci Rural Pract"},{"year":"2018","series-title":"Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families [Internet]","key":"10.1016\/j.ajem.2021.10.012_bb0065"},{"key":"10.1016\/j.ajem.2021.10.012_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.ajem.2021.10.012_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort studymortality and medication for opioid use disorder after overdose","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ajem.2021.10.012_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16228","article-title":"Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-associated infective endocarditis","volume":"3","author":"Kimmel","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ajem.2021.10.012_bb0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jelectrocard.2013.12.002","article-title":"Racial susceptibility for QT prolongation in acute drug overdoses","volume":"47","author":"Manini","year":"2014","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.ajem.2021.10.012_bb0090","first-page":"1","article-title":"Racial disparities in the treatment of acute overdose in the emergency department","volume":"12","author":"Wilder","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"10.1016\/j.ajem.2021.10.012_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajem.2021.10.012_bb0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths \u2014 United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675721008469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675721008469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:56:03Z","timestamp":1760025363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675721008469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"alternative-id":["S0735675721008469"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2021.10.012","relation":{},"ISSN":["0735-6757"],"issn-type":[{"type":"print","value":"0735-6757"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2021.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}